GlassScriptPhysician profile
Samantha Lee Kyvik
NPI 1184246472
$4,693.21
in general payments reported to CMS, 2019-2025
21 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $853 · 2023: $979 · 2024: $1,156 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.65 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $589.82 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $429.77 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $426.53 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $392.48 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $242.02 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $147.15 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $125.85 | 2023-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $118.92 | 2023-2025 | Zoryve |
| Incyte Corporation | $94.56 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $88.39 | 2021-2025 | |
| Galderma Laboratories, L.P. | $73.03 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.11 | 2023-2024 | Spevigo |
| Organon LLC | $50.13 | 2025 | Vtama |
| Genzyme Corporation | $45.67 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $42.80 | 2024 | Daxxify |
| Ucb, INC. | $39.42 | 2022 | |
| Dermavant Sciences, INC. | $38.33 | 2024 | Vtama |
| Pfizer INC. | $37.48 | 2023-2024 | |
| Verrica Pharmaceuticals INC. | $24.36 | 2023 | Ycanth |
| Biofrontera INC. | $20.41 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Kyvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.